These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 21333749)

  • 1. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.
    Zhang YJ; Duan Y; Zheng XF
    Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates of mTOR inhibitors.
    Zhou H; Luo Y; Huang S
    Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting mTOR signaling pathway in ovarian cancer.
    Mabuchi S; Hisamatsu T; Kimura T
    Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR signaling and drug development in cancer.
    Dancey J
    Nat Rev Clin Oncol; 2010 Apr; 7(4):209-19. PubMed ID: 20234352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
    Smolewski P
    Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.
    Lv X; Ma X; Hu Y
    Expert Opin Drug Discov; 2013 Aug; 8(8):991-1012. PubMed ID: 23668243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming resistance to rapalogs in gliomas by combinatory therapies.
    Grzmil M; Hemmings BA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1371-80. PubMed ID: 23395884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status and challenges associated with targeting mTOR for cancer therapy.
    Dowling RJ; Pollak M; Sonenberg N
    BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR kinase inhibitors as potential cancer therapeutic drugs.
    Sun SY
    Cancer Lett; 2013 Oct; 340(1):1-8. PubMed ID: 23792225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.
    Mohindra NA; Platanias LC
    Leuk Lymphoma; 2015; 56(9):2518-23. PubMed ID: 25747970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
    Khokhar NZ; Altman JK; Platanias LC
    Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
    Magaway C; Kim E; Jacinto E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pushing the envelope in the mTOR pathway: the second generation of inhibitors.
    Vilar E; Perez-Garcia J; Tabernero J
    Mol Cancer Ther; 2011 Mar; 10(3):395-403. PubMed ID: 21216931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP-competitive inhibitors of mTOR: an update.
    Schenone S; Brullo C; Musumeci F; Radi M; Botta M
    Curr Med Chem; 2011; 18(20):2995-3014. PubMed ID: 21651476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin passes the torch: a new generation of mTOR inhibitors.
    Benjamin D; Colombi M; Moroni C; Hall MN
    Nat Rev Drug Discov; 2011 Oct; 10(11):868-80. PubMed ID: 22037041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
    Rao RD; Buckner JC; Sarkaria JN
    Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.